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Abstract
Background: Ralstonia spp, an environmental microorganism, has been occasionally associated with healthcare
infections. The aim of this study was to investigate an outbreak caused by Ralstonia mannitolilytica in oncology
patients.
Methods: Case definition: Oncology outpatients attending a day ward, with positive blood and/or central venous
catheter (CVC) culture for Ralstonia spp from September 2013 – June 2014. We analysed medical records,
procedures and environmental samples. R. mannitolilytica was identified by 16S rRNA sequencing, and typed
by Pulsed Field Gel Electrophoresis (PFGE); resistance to carbapenemes was investigated by phenotypic and
molecular methods.
Results: The patients (N = 22) had different malignancies and received different therapy; all had a CVC and 16
patients presented chills and/or fever. R. mannitolilytica was isolated from both blood and CVC (n = 12) or only
blood (n = 6) or CVC tips (n = 4). The isolates had indistinguishable PFGE profile, and showed resistance to
carbapenems. All the isolates were negative for carbapenemase genes while phenotypic tests suggests the
presence of an AmpC β-lactamase activity,responsible for carbapenem resistance. All patients had had CVC flushed
with saline to keep the venous access pervious or before receiving chemotherapy at various times before the onset
of symptoms. After the first four cases occurred, the multi-dose saline bottles used for CVC flushing were replaced
with single-dose vials; environmental samples were negative for R. mannitolilytica.
Conclusions: Although the source of R. mannitolilytica remains unidentified, CVC flushing with contaminated saline
solution seems to be the most likely origin of R. mannitolilytica CVC colonization and subsequent infections. In
order to prevent similar outbreaks we recommend removal of any CVC that is no longer necessary and the use
of single-dose solutions for any parenteral treatment of oncology patients.
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Background
The genus Ralstonia comprises a group of non-
fermentative, Gram-negative bacteria (NFGN) found in
moist environments, such as water, soil and plants [1].
Three Ralstonia species, Ralstonia pickettii, Ralstonia insi-
diosa and Ralstonia mannitolilytica, formerly designated
Burkholderia pickettii, Burkholderia solanacearum and
Pseudomonas thomasii, respectively, have been recognized
as opportunistic human pathogens [1]. Their relevance
has been currently re-evaluated because of their ability
to survive in different types of disinfectants and to pass
through 0.2-μm filters that are used to sterilize solu-
tions [1, 2].
Ralstonia spp. is reported as a causative agent of
bacteremia [3, 4], meningitis [5, 6], and sepsis [7, 8] in
immunocompromised patients and of central venous
catheter (CVC)-associated bacteremia in oncology pa-
tients [1–4, 9]. Several hospital outbreaks have been
described that were associated with contaminated solu-
tions, including water for injection, saline solutions,
disinfectants and antiseptics [1]. Multidrug resistance
in NFGN is widely reported in the literature [10, 11]
and is causing increasing concern because such bacteria
may have a role not only as human pathogens but also
as potential reservoirs of resistance genes, particularly
when they are found in hospital settings. Several studies
have described resistance to fluoroquinolones, 3rd gen-
eration cephalosporin and carbapenems [1] in isolates
belonging to all the three Ralstonia species.
R. pickettii is the Ralstonia species most frequently
reported in the literature while only a limited number
of infections are attributed to R. insidiosa and R. mannito-
lilytica [1]. The clinical importance of these two species is
probably underestimated because their biochemical
patterns are similar to that of R. pickettii, making it impos-
sible their distinction based on conventional microbio-
logical tests only [1, 4, 12, 13].
Here we describe an outbreak caused by R. mannitoli-
lytica in patients attending a day ward unit in an oncol-




The Istituto Nazionale Tumori Regina Elena – Istituto
Dermatologico San Gallicano is a 215-bed hospital lo-
cated in Rome with approximately 6,700 inpatient ad-
missions and 900,000 outpatients visits per year. The
hospital has two oncology day wards (DW-A and DW-B)
located in different buildings, each consisting of a single
therapy room with 20 bays for chemotherapy infusion and
attended by an average of 65 patients/day. Patients are
assigned to either ward while the infusion bays are
not pre-assigned neither a register for the allocation
of patients to bays is in place. One of the units (DW-A)
was affected by the outbreak and was the object of the epi-
demiological investigation. From September 2013 – June
2014, 2485 patients attended DW-A for a total of 20,177
day-hospital visits.
Epidemiological investigation
We defined a case as a patient attending DW-A from
September 2013 – June 2014 that had a blood culture
and/or a CVC tip culture positive for Ralstonia spp. with
or without symptoms (chills and/or fever). Two of the
authors (CL, LI) assisted by an infection control nurse
(MF) reviewed all the medical records of the cases to iden-
tify any common medical procedure or any occurrence
that might have posed a risk for acquiring Ralstonia spp.
infection.
Environmental sampling
Environmental sampling started on 17 October 2013,
immediately after Ralstonia spp. had been isolated from
the blood culture of the third case. Laboratory techni-
cians collected the samples using commercially available
sterile swabs (COPAN Eswabs, Brescia, Italy), following
existing departmental guidelines, in the therapy room
from furniture and electronic devices (N = 8), and in the
drug preparation room (N = 8) from personal computer,
telephone, fax, medicine cabinet, medicine trolley. Swabs
were cultured in Tryptic Soy Broth, incubated for 48 h
at 37°C, and plated on chocolate agar and blood agar.
Samples were also obtained from liquid soaps (N = 10),
their dispensers (N = 8) and chlorhexidine (N = 4) in use
in DW-A. In addition distilled water and sterile water
used for injection were cultured as described in Moreira
et al. [14].
Microbiological methods and typing of isolates
Blood samples were taken through CVC in all patients. R.
mannitolilytica was isolated from signal-positive blood
culture bottles (BacT/ALERT BioMérieux, Florence, Italy)
using conventional methods. Sixteen CVC tips were cul-
tured according to Zhang et al. [15].
Identification of the isolates was obtained by VITEK 2
system (BioMérieux, Florence, Italy). Identification at the
species level was obtained by amplification of the 16S
rDNA gene followed by double-strand sequencing [16].
To investigate the relatedness of Ralstonia isolates,
PFGE was performed on all isolates obtained from blood
cultures and CVC tip cultures, following digestion of gen-
omic DNA by the restriction enzyme SpeI (New Englands
Biolabs, Ipswich, MA), according to the CDC protocol
(available at https://www.cdc.gov/pulsenet/pdf/ecoli-
shigella-salmonella-pfge-protocol-508c.pdf ) with
addition of 50 μM thiourea in the agarose gel and in
the electrophoresis running buffer. The following
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running conditions were used: 120 costant angle at 6V/
cm, with pulse time 20h 1s-40s, 4h 30s-60s. Salmonella
Braenderup H9812 was used as reference for molecular
size.
Antibiotic susceptibility of the isolates
Susceptibility testing of the isolates was performed by the
disk diffusion method according to the EUCAST guidelines
(available at http://www.eucast.org/clinical_breakpoints/).
The antimicrobials tested were: ceftazidime, meropenem,
ciprofloxacin, gentamicin, amikacin, and piperacillin/
tazobactam (Becton Dickinson, Milan, Italy). Antimicro-
bial susceptibility to piperacillin/tazobactam was con-
firmed by Etest (BioMérieux, Florence, Italy). As there are
no EUCAST susceptibility breakpoints available for Ral-
stonia spp., the results were interpreted using the
EUCAST criteria for Pseudomonas spp. Pseudomonas
aeruginosa ATCC 27853 was included as control.
Identification of determinants of carbapenem-resistance
Four outbreak isolates (A, E, L, S) were randomly selected
to perform the phenotypic and molecular tests. Identifica-
tion of resistance mechanisms for carbapenems was per-
formed by the agar tablet/disc diffusion method (KPC/
MBL and OXA-48 Confirm Kit, ROSCO Diagnostica A/S,
Taastrup, Denmark). In addition, PCR assays were per-
formed for the identification of the chromosomal genes
blaOXA-443 and blaOXA-444, previously described in a
carbapenem-resistant R. mannitolilytica strain [17]. For
amplification of the two genes, two couple of primers
were designed: OXA-443 Fw 5’-ATGACGAAACTCC
GCCA-3’/OXA-443 Rv 5’-AGGTGGGCTCGATCTTG-3’
and OXA-444 Fw 5’-ATGTTCTCTCGTTGGTC-3’/
OXA-444 Rv 5’- TGCGGGTCGGACGGAGA -3’. The
presence of other carbapenem-resistance genes was inves-
tigated by multiplex PCR assay with primers designed to
amplify the following 11 genes: blaIMP, blaVIM, blaNDM,
blaSPM, blaAIM, blaDIM, blaGIM, blaSIM, blaKPC, blaBIC, and
blaOXA-48, accordingly to Poirel et al. [18].
Control strains
All the experiments were performed using two controls
strains: R. mannitolilytica BK931 [2] and R. mannitolilytica
ATCC BAA-716 (LMG 6866) [13].
Results
Epidemiological and microbiological investigation
According to case definition, we identified 22 patients
(attack rate 0,88%), 13 males and 9 females, age range
30–84 years old (median age 66), attending DW-A from
24 September 2013 – 23 June 2014 (Fig. 1, Table 1). In
particular, 12 patients had Ralstonia spp. positive cul-
tures from both blood and the CVC tip; four patients
didn’t have blood culture performed, but because of the
clinical symptoms their catheters were removed and cul-
tured and were found positive for Ralstonia spp.; other
six patients had a positive blood culture but the CVC
tips were not tested.
Analysis of the medical records revealed that the pa-
tients had different types of CVC, in particular 20 had a
Port, while two had a PICC (percutaneous introduction
central catheter). We were able to retrieve the insertion
dates of the devices for 13 out of 22 patients: they were
inserted from more than 4 years to less than 2 months
before the onset of symptoms (Table 1). The patients
had different types of solid cancer, they underwent
different therapeutic protocols and attended DW-A in
different days. The only common procedure among the
patients that we were able to identify was a maintenance
procedure, which consisted in flushing saline solution
through the CVC, after disinfection with 2% chlorhexidine
gluconate in 70% isopropyl alcohol. Such procedure was
performed either before the patient received chemother-
apy or as a periodic standard procedure to keep the pa-
tient’s venous access pervious. Sixteen patients reported
fever and/or chills while receiving chemotherapy through
CVC or within two hours after the CVC flushing proced-
ure. No information was available for the remaining six
patients. No patient had signs of skin infection at the Port
Fig. 1 Epidemic curve of cases of R. mannitolilytica in oncology patients attending the day hospital ward A, September 2013-June 2014
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site or at the PICC insertion site. Empirical antibiotic ther-
apy (ciprofloxacin) was deemed necessary for one patient
only. All patients had their CVCs removed and this led to
resolution of symptoms in all cases.
The review of the current medical practices of DW-
A revealed that, between August 2013 and September
2013, five bottles of saline solution of 250 ml were
used for CVC flushing. This type of bottle was in use
only in DW-A, and not in DW-B, and usually
remained in use for two days from opening. All the
cases attended the DW-A for CVC flushing when the
250 ml bottles of saline solution were in use. After
the occurrence of the first three cases, the hospital
committee for control of healthcare-associated infec-
tion gave indications to perform environmental cul-
tures and room disinfection (mid October). However,
since the 250 ml bottles of saline solution had been
already discarded and replaced with single-dose vials,
they were unavailable for microbiological testing when
the investigation was started. All the environmental
samples and samples from chlorhexidine, distilled
water and sterile water were negative for the presence
of Ralstonia spp.
Characterization of the pathogen
Ralstonia spp. had never been isolated from any patients
in the hospital both before and after the outbreak. By
routine biochemical tests the isolates from blood and
CVC tips were identified as R. pickettii. However, 16S
rDNA sequencing showed that the isolates were in fact
R. mannitolilytica. In addition, all the isolates shared an
indistinguishable PFGE profile (Fig. 2) while the two
control strains (ATCC BAA-716 and BK931), showed
profiles that were distinct from those of the outbreak
strains. The outbreak strains had the same multi-drug
resistance profile: they were resistant to ceftazidime,
meropenem, ciprofloxacin, gentamicin, and amikacin but
were susceptible to piperacillin/tazobactam (MIC ≤16
mg/L). Except for susceptibility to ciprofloxacin, the two
control strains had the same resistance pattern.
Regarding resistance to carbapenems the strains were
negative for the presence of the 11 carbapenemase genes
screened by multiplex PCR. All the isolates tested, includ-
ing the two controls, were positive by PCR for the blaOXA-
443 and blaOXA-444 genes. Phenotypic tests performed to
assess the mechanism of carbapenem resistance showed
that cloxacillin was able to abolish meropenem resistance,
Table 1 Data of the 22 cases (A-V) of R. mannitolilytica outbreak, September 2013-June 2014, oncology hospital in Rome
Patient Sex Age Type of CVC Date of implantation Date of diagnosis Blood culture Tip CVC culture
A F 62 PICC 08/08/2013 24/09/2013 + ND
B M 56 Port 07/06/2011 02/10/2013 + ND
C M 84 Port 18/09/2012 16/10/2013 + +
D M 66 Port 02/04/2013 16/10/2013 + +
E F 66 Port 13/12/2011 24/10/2013 + +
F F 62 PICC 10/06/2013 24/10/2013 + ND
G F 73 Port 31/05/2011 28/10/2013 + +
H F 65 Port NA 07/11/2013 + +
I M 67 Port 13/12/2011 29/11/2013 + +
J M 56 Port NA 03/12/2013 + +
K F 30 Port 25/09/2012 14/12/2013 + +
L F 65 Port NA 20/12/2013 ND +
M M 62 Port 10/10/2010 23/12/2013 + +
N F 72 Port NA 07/01/2014 + +
O M 77 Port NA 09/01/2014 + ND
P F 67 Port NA 14/01/2014 ND +
Q M 80 Port 15/04/2009 30/01/2014 + ND
R F 80 Port NA 14/02/2014 + ND
S F 63 Port NA 21/02/2014 + +
T M 70 Port NA 27/02/2014 + +
U M 61 Port 31/01/2013 12/06/2014 ND +
V M 61 Port 05/12/2011 23/06/2014 ND +
NA: not available; ND: not determined
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thus suggesting the presence of an AmpC β-lactamase
activity.
Discussion
The microbiological and epidemiological investigation of
this outbreak did not detect the source of the contamin-
ation, however the molecular typing of the pathogen
strongly supports the hypothesis of a common source of
contamination. Failure to identify the culprit is probably
due to the fact that when the investigation was started
samples from disinfectants, antiseptics and saline solu-
tions used at the beginning of the outbreak were not
available for microbiological investigation. In fact, disin-
fectants, antiseptics and multi-dose bottles of saline so-
lution have been described in the literature as one of the
main sources for Ralstonia spp. contamination [1],
therefore their prompt removal from DW-A immedi-
ately after the beginning of the outbreak was the most
understandable precaution to adopt from the patients’
safety viewpoint. However, in spite of the multi-dose
bottles of saline solution removal, the outbreak lasted
9 months. Indeed, the revision of the medical records
showed that CVC flushing with saline solution was a com-
mon procedure adopted with all the patients and that, at
the beginning of the outbreak, multi-dose bottles of saline
solution were in use in DW-A. Thus it is very likely that
patients were exposed to one or more contaminated bot-
tle(s) of saline. The majority of the patient developed clin-
ical symptoms immediately thereafter, while others likely
had a CVC colonization by R. mannitolilytica. Any subse-
quent procedure through CVC, chemotherapy or new
saline flushing, may have caused detachment and dissem-
ination of R. mannitolilytica from CVC, causing fever and
chills. This might have happened even after several weeks
from CVC colonization, possibly accounting for the pro-
tracted duration of the outbreak. A similar finding have
been reported by Raveh et al. [19] in which, a patient
with a CVC developed fever and chills and his blood
culture was positive for R. pickettii. The patient was
treated with antibiotic therapy and the CVC was left in
place. However 15 months later the patient developed
another bloodstream infection with the same organism
likely colonizing CVC.
The ability to grow as biofilm on abiotic surfaces
plays an important role in colonization of hospital
equipment and indwelling medical devices such as
CVCs [20]. Ability to form biofilm has been de-
scribed in different Ralstonia species including also
R. mannitolylitica [21–24]. It is conceivable that biofilm
formation might have played a role for these strains to
allow adherence to CVCs and subsequent dissemination
in the host, following the flushing procedures of the
device.
The prolonged duration of this outbreak is not unpre-
cedented for this pathogen. Daxboeck et al. [4] reported
isolation of R. mannitolilytica in 30 patients attending
15 different wards between February 2002 and March
2004; in this study also the source was not identified.
Other outbreaks have been reported in pediatric pa-
tients, associated with oxygen delivery devices [25, 26]
and in oncology patients [1, 2]. In the outbreak de-
scribed by Gröbner et al. [2], which lasted 11 weeks,
the source was not identified but it was hypothesized
Fig. 2 Pulsed-field gel electrophoresis (PFGE) of R. mannitolilytica
strains. M: Molecular weight standard, Salmonella Braenderup H9812.
A: strain isolated from blood culture. U, V: strains isolated from CVC.
These strains are representative of the entire sample. BK931, ATCC
BAA-716: control strains
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that a contaminated solution administered through
CVC could have been the culprit.
It is important to underline that the misuse of multidose
vials, as in our outbreak, has been frequently reported as a
cause of numerous outbreaks [27–30] in different Euro-
pean countries as well as in USA where the CDC is aware
of at least 49 outbreaks occurred in 13 years [31]. There-
fore the correct use of single dose vials, for a single pa-
tient, is an effective and important way to prevent
outbreaks as reported by specific guidelines [32].
R. mannitolilytica is frequently recognized as a multire-
sistant microorganism [4, 33–35] but limited data are
available about carbapenem-resistance. To the best of our
knowledge, only a limited number of studies so far, have
tested susceptibility to this drug: in four studies, all the
strains tested were resistant (five in one study and one
strain each in the other three) [2, 17, 33] while Daxboeck
et al. [4] reported carbapenem-resistance in 12 strains out
of 30. In our isolates no carbapenemase genes were de-
tected, but they were positive for the chromosomal genes
blaOXA-443 and blaOXA-444, that have been previously de-
scribed in one R. mannitolilytica carbapenem-resistant
strain [17] and that bear close similarity to the blaOXA-22
and blaOXA-60 genes found in R. pickettii [36]. blaOXA-22
and blaOXA-60 code for two oxacillinase, a narrow
spectrum oxacillinase and an inducible carbapenemase,
respectively, although none of them was found to be re-
sponsible for carbapenem resistance in R. pickettii [36,
37]. In addition, the cloxacillin test suggested that the
R. mannitolilytica isolates were positive for the pres-
ence of AmpC β-lactamases. These enzymes are clinic-
ally important because they may confer resistance to a
wide variety of β-lactam drugs, narrow-, expanded-,
and broad-spectrum cephalosporins, β-lactam-β-lacta-
mase-inhibitor drugs combinations, as well as to aztre-
onam and carbapenems in case of association with
altered porins and/ or efflux mechanisms [38]. Taken
together, our data suggest that meropenem resistance
was likely due to overproduction of AmpC β-lactamase,
possibly in synergy with a second mechanism (e.g. de-
creased production of the porin channel and/or activa-
tion of efflux systems). Recently, a serin-hydrolase class
C family β-lactamase has been identified in R. mannito-
lilytica (GenBank accession number: WP_045219476)
[15], therefore production of this enzyme may contrib-
ute to carbapenem resistance.
Although R. mannitolilytica did not cause life-
threatening infections in this outbreak as well as in pre-
viously reported outbreaks [2, 26], the increased detec-
tion of Ralstonia spp. in healthcare settings coupled
with the emergence of multi-resistant strains of R.
mannitolilytica, represent a reason of concern, particu-
larly in case of vulnerable patients which may require
an antimicrobial therapy.
Conclusion
We reported the first outbreak due to R. mannitolilytica
in oncology patients bearing CVC in Italy. Although the
source of the outbreak could not be readily identified,
the investigation suggested that contaminated saline so-
lution used for CVC flushing may have been the source
of the outbreak. In order to prevent possible infections
we recommend the removal of any CVC that is not lon-
ger necessary and the use of single dose solutions for
any parenteral treatment of cancer patients.
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